ArticleMedical oncology (Northwood, London, England)2014
Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 89 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 6 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Pooled it
- The Significance of Long Non-coding RNA HULC in Predicting Prognosis and Metastasis of Cancers: a Meta-Analysis.Pathology oncology research : POR · 2019Pooled it
- TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.Medicine · 2017Pooled it
- Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis.Oncotarget · 2017Pooled it
- Single nucleotide polymorphisms in ZNRD1-AS1 increase cancer risk in an Asian population.Oncotarget · 2017Pooled it
- AlncRNA HULC as an effective biomarker for surveillance of the outcome of cancer: A meta-analysis.PloS one · 2017Pooled it
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- The Role of Long Noncoding RNAs in Progression of Leukemia: Based on Chromosomal Location.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Lnc-HULC, miR-122, and sirtulin-1 as potential diagnostic biomarkers for psoriasis and their association with the development of metabolic syndrome during the disease course.Non-coding RNA research · 2023Article
- GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway.BMC cancer · 2023Article
- MiRNA-200b level in peripheral blood predicts renal interstitial injury in patients with diabetic nephropathy.Journal of medical biochemistry · 2023Article
- LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities.Genes · 2022Review
- LINC01094 promotes pancreatic cancer progression by sponging miR-577 to regulate LIN28B expression and the PI3K/AKT pathway.Molecular therapy. Nucleic acids · 2021Article
- LncRNAs: Novel Biomarkers for Pancreatic Cancer.Biomolecules · 2021Review
- The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant).Cancer cell international · 2021Review
- Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy.Translational oncology · 2021Review
- Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor.Cancers · 2021Review
- Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.Oncology letters · 2021Review
- Identifying modules of cooperating cancer drivers.Molecular systems biology · 2021Article
- Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2025-03-28Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of/in Article · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is the fourth leading cause of cancer-related mortalities in the USA and the sixth leading cause of mortality in China. Recent studies have shown that lncRNAs play important roles in carcinogenesis. The aim of this study was to explore the role of lncRNA HULC in PC. Quantitative real-time PCR was performed to investigate the expression of HULC in tumor tissues and corresponding normal tissues from 304 patients with PC. The higher expression of HULC was significantly correlated with large tumor size, advanced lymph node metastasis and vascular invasion. Multivariate analyses revealed that HULC expression served as an independent predictor for overall survival (P = 0.032). Further experiments revealed that HULC knockdown significantly repressed cell proliferation of PC in vitro. In conclusion, our results suggest that HULC may serve as a candidate prognostic biomarker through growth regulation in human PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.